A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 157,800 shares of PLRX stock, worth $1.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
157,800
Previous 189,700 16.82%
Holding current value
$1.94 Million
Previous $2.04 Million 13.29%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.52 - $14.35 $335,588 - $457,765
-31,900 Reduced 16.82%
157,800 $1.77 Million
Q2 2024

Aug 14, 2024

BUY
$10.58 - $15.61 $425,316 - $627,522
40,200 Added 26.89%
189,700 $2.04 Million
Q1 2024

May 15, 2024

BUY
$14.14 - $19.59 $804,566 - $1.11 Million
56,900 Added 61.45%
149,500 $2.23 Million
Q4 2023

Feb 14, 2024

SELL
$12.85 - $19.15 $884,080 - $1.32 Million
-68,800 Reduced 42.63%
92,600 $1.68 Million
Q3 2023

Nov 14, 2023

SELL
$14.58 - $20.15 $497,178 - $687,115
-34,100 Reduced 17.44%
161,400 $2.8 Million
Q2 2023

Aug 14, 2023

SELL
$18.12 - $30.56 $1.32 Million - $2.22 Million
-72,800 Reduced 27.13%
195,500 $3.54 Million
Q1 2023

May 15, 2023

BUY
$18.73 - $36.26 $1.71 Million - $3.3 Million
91,100 Added 51.41%
268,300 $7.14 Million
Q4 2022

Feb 14, 2023

BUY
$17.0 - $25.43 $1.3 Million - $1.95 Million
76,600 Added 76.14%
177,200 $3.43 Million
Q3 2022

Nov 14, 2022

BUY
$7.67 - $24.23 $348,218 - $1.1 Million
45,400 Added 82.25%
100,600 $2.1 Million
Q2 2022

Aug 15, 2022

SELL
$4.11 - $8.75 $90,009 - $191,625
-21,900 Reduced 28.4%
55,200 $442,000
Q1 2022

May 16, 2022

BUY
$7.01 - $14.1 $222,217 - $446,970
31,700 Added 69.82%
77,100 $540,000
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.26 $557,058 - $829,004
45,400 New
45,400 $613,000

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $600M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.